Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Base Study	STARTED	Odanacatib 50 mg OW	8,043
Base Study	STARTED	Placebo	8,028
Base Study	COMPLETED	Odanacatib 50 mg OW	4,297
Base Study	COMPLETED	Placebo	3,960
Base Study	NOT COMPLETED	Odanacatib 50 mg OW	3,746
Base Study	NOT COMPLETED	Placebo	4,068
First Extension Study	STARTED	Odanacatib 50 mg OW	4,297
First Extension Study	STARTED	Placebo	3,960
First Extension Study	COMPLETED	Odanacatib 50 mg OW	3,144
First Extension Study	COMPLETED	Placebo	2,309
First Extension Study	NOT COMPLETED	Odanacatib 50 mg OW	1,153
First Extension Study	NOT COMPLETED	Placebo	1,651
Second Extension Study	STARTED	Odanacatib 50 mg OW	3,144
Second Extension Study	STARTED	Placebo	2,309
Second Extension Study	COMPLETED	Odanacatib 50 mg OW	2,844
Second Extension Study	COMPLETED	Placebo	2,112
Second Extension Study	NOT COMPLETED	Odanacatib 50 mg OW	300
Second Extension Study	NOT COMPLETED	Placebo	197

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00529373/flow